Press Release

Printer Friendly Version View printer-friendly version
Back
ReWalk Announces Launch of 522 Post-Market Study with Stanford University School of Medicine as Lead Investigator Site
Oracle Contracted for Electronic Data Capture System to Manage Study Data

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Aug. 2, 2016 /PRNewswire/ -- Leading exoskeleton manufacturer and developer ReWalk Robotics (NASDAQ: RWLK) announced the initiation of its U.S. Food and Drug Administration (FDA) Section 522 post-market study with the Stanford University School of Medicine listed as the lead study center.  Dr. Matthew Smuck, associate professor of orthopaedic surgery and medical director of rehabilitation services for Stanford Health Care, will serve as lead investigator.  The trial has already enrolled two patients

ReWalk Robotics logo

The 522 study will follow 60 patients for one year, and will include as many as 15 centers across the country. ReWalk has contracted with Oracle, the industry leader in electronic data capture systems (EDS), to oversee the data management of the study.

"ReWalk is pleased the study is underway with patients enrolled at the lead investigator site. We believe this will contribute to the growing body of data supporting the benefits of exoskeleton technology, and this study will serve to underscore the impact of exoskeleton technology on the health and well-being of the end user," said Larry Jasinski, President and CEO of ReWalk Robotics. 

ReWalk Robotics is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk. ReWalk is the first exoskeleton system to receive FDA clearance for use in the home as well as in the rehabilitation setting.  ReWalk received FDA clearance in June 2014.

About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

Forward Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases.  The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control.  Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's ability to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's ability to improve its products, develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission on February 29, 2016 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission.  Any forward-looking statement made in this press release speaks only as of the date hereof.  Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them.  Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Logo - http://photos.prnewswire.com/prnh/20150713/235995LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rewalk-announces-launch-of-522-post-market-study-with-stanford-university-school-of-medicine-as-lead-investigator-site-300307282.html

SOURCE ReWalk Robotics

ReWalk Robotics, Jennifer Wlach, 202-261-4000, media@rewalk.com; Investor Relations Contact: Lisa M. Wilson, In-Site Communications, Inc., 917-543-9932, lwilson@insitecony.com